Scorpion Therapeutics, Inc.

The outlook for biopharmaceutical company financings has grown increasingly grim in 2025 as drug developer valuations remain challenged by various macroeconomic and industry-specific concerns. New dat

Eli Lilly and Verve Therapeutics agreed to a buyout on June 17 valued at approximately $1bn with a contingent value right (CVR) that could be attainable, bringing the total deal value to around $1.3bn

Eli Lilly showed its confidence in Scorpion Therapeutics’ precision drug development efforts by agreeing in January to pay up to $2.5bn for the company to access its lead drug candidate, the PI3Kα i

Biopharma merger and acquisition value for the first quarter of 2025 reached $38.4bn from 41 transactions, 22 of which had disclosed values. Making up almost 38% of that total was Johnson & Johnso